Literature DB >> 19130464

Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.

Joshua S Hill1, James T McPhee, Theodore P McDade, Zheng Zhou, Mary E Sullivan, Giles F Whalen, Jennifer F Tseng.   

Abstract

BACKGROUND: Although surgical resection is generally recommended for patients with localized pancreatic neuroendocrine tumors (PNETs), the impact of resection on overall survival is unknown. The authors investigated the survival advantage of pancreatic resection using a national database.
METHODS: This is a retrospective survival analysis of patients with PNETs from the Surveillance, Epidemiology, and End Results database (1988-2002).
RESULTS: A total of 728 patients with PNETs were identified with a median survival of 43 months using Kaplan-Meier survival methods. Resection of tumor was associated with significantly improved survival compared with those patients who were recommended for but did not undergo resection (114 months vs 35 months; P < .0001). This survival benefit was demonstrated for patients with localized, regional, and metastatic disease. A multivariable Cox proportional hazards model was constructed to assess the overall effect of surgical resection on survival, and demonstrated an adjusted odds ratio of 0.48 (95% confidence interval, 0.35-0.66) compared with those who were recommended for surgery but did not proceed to surgery.
CONCLUSIONS: The authors have demonstrated in a large national study that resection of primary tumor in patients with PNETs is associated with improved survival across all disease stages. Patients with localized, regional, and metastatic PNETs who are reasonable operative candidates should be considered for resection of their primary tumors. (c) 2009 American Cancer Society.

Entities:  

Mesh:

Year:  2009        PMID: 19130464     DOI: 10.1002/cncr.24065

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  104 in total

1.  Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes.

Authors:  Christina L Roland; Aihua Bian; John C Mansour; Adam C Yopp; Glen C Balch; Rohit Sharma; Xian-Jin Xie; Roderich E Schwarz
Journal:  J Surg Oncol       Date:  2011-10-17       Impact factor: 3.454

Review 2.  [Classification and malignant potential of pancreatic cystic tumors].

Authors:  I Esposito; A M Schlitter; B Sipos; G Klöppel
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

3.  Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors.

Authors:  Laura Prakash; Priya Bhosale; Jordan Cloyd; Michael Kim; Nathan Parker; James Yao; Arvind Dasari; Daniel Halperin; Thomas Aloia; Jeffrey E Lee; Jean Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2016-09-15       Impact factor: 3.452

Review 4.  Surgical resection of pancreatic neuroendocrine neoplasm by minimally invasive surgery-the robotic approach?

Authors:  Roxanne Y A Teo; Brian K P Goh
Journal:  Gland Surg       Date:  2018-02

5.  Pancreastatin predicts survival in neuroendocrine tumors.

Authors:  Scott K Sherman; Jessica E Maxwell; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Ann Surg Oncol       Date:  2014-04-22       Impact factor: 5.344

Review 6.  Practical management and treatment of pancreatic neuroendocrine tumors.

Authors:  Naoko Iwahashi Kondo; Yasuharu Ikeda
Journal:  Gland Surg       Date:  2014-11

7.  Natural History and Treatment Trends in Pancreatic Cancer Subtypes.

Authors:  Courtney J Pokrzywa; Daniel E Abbott; Kristina A Matkowskyj; Sean M Ronnekleiv-Kelly; Emily R Winslow; Sharon M Weber; Alexander V Fisher
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

Review 8.  Laparoscopic resection of pancreatic neuroendocrine tumors.

Authors:  Abbas Al-Kurd; Katya Chapchay; Simona Grozinsky-Glasberg; Haggi Mazeh
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 9.  Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2015-10-31       Impact factor: 3.495

10.  Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy.

Authors:  Su-Jung Kim; Jin Won Kim; Sae-Won Han; Do-Youn Oh; Se-Hoon Lee; Dong-Wan Kim; Seock-Ah Im; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2010-08-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.